CVS Health Corporation is american stock pharmacy operator offering nice sell opportunities at new supply imbalances created on both the weekly and the monthly timeframes with everything pointing down in a clear downtrend with new supply levels being created and demand levels being eliminated. Strong imbalances created on the way down.Two new supply levels have...
NVS Novartis owns or makes a slew of pharmacopial needs for a variety of medical needs.
Little dip during recent pullback.
Watching Friday ads, all brand names no companies. All Novartis or made for another company by Novartis.
Medical stock that's too thinly traded got mixed review on clinical trial results on Tivozanib, which showed efficacy, just not to level expected and testing new low for 2018 at 2.03 and below full fibonacci retracement of 2.10 as prior low. NASDAQ:AVEO
CBDS CVSI GWPHINSY OTC:EMHTF
CBD oil as extracted from PCR HEMP has many pharmacological/nutraceutical benefits.
* Sleeping better
* Relieves stress / reducing anxiety
* Pain Relief & joint pain - and is non-psychotropic (PCR HEMP contains < 0.3% THC and often less in CBD Oils)
* Epilepsy and epileptic seizures
* IBS/Crohn's disease studies in process
BLRX had a strong rally today and it's just getting started.
In the related idea my price target was $1.34.
Today's high was $1.78
Check out the weekly chart:
$1.34 was 1.618 extension level from Waves 1 & 2.
Since the price-action broke $1.34 we will have an extended 3rd wave.
I expect a very strong...
The price has closed above the downtrend line started this year with consistent volumes. I opened a buy as I am expecting increasing volume and strenght in the next sessions. Tps are already highlighted on the right.
As showed in the chart $BHC comes from a long bullish flag. Price is reaching the buy zone where the major bullish trendline goes through. It's not yet a buy but we are approching such zone. Strategy: watch and wait.
I am waiting for an entry long in $BHC but positive signs are already there especially RSI is giving an insight, MA 200 is almost close and it might be probable a new test. Monthly RSI is down and on a weekly basis price is approcing the pullback of the third bullish wave.
For the time being, given the positive earnings release a bullish trend continuation is...
BL-8040 is a novel, short peptide that functions as a high-affinity antagonist for CXCR4, which BioLineRx is developing for the treatment of solid tumors, acute myeloid leukemia, or AML, and stem-cell mobilization for bone-marrow transplantation.
In January 2016, BioLineRx entered into a collaboration with MSD, known as Merck...